October 30th 2024
Daniel DeAngelo, MD, PhD, discusses the evolving role of JAK inhibitors in the management of myelofibrosis and highlights remaining unmet needs for this patient population.
Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies
June 22nd 2022
Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.
March 23rd 2022
Daniel J. DeAngelo, MD, PhD, discusses the exploration of uproleselan plus chemotherapy in relapsed/refractory acute myeloid leukemia.
September 27th 2021
The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.
September 15th 2021
Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
January 13th 2021
Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.
December 15th 2020
Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.
July 21st 2020
Daniel J. DeAngelo, MD, PhD, discusses the utility of the investigational agent pevonedistat in myelodysplastic syndrome.
February 27th 2018
Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).
July 26th 2016